

Vimian announces new financial targets

The Board of Directors of Vimian AB (publ) has today adopted new financial targets. Since the previous financial targets were set three years ago, Vimian has more than doubled its revenues and adjusted EBITA through strong organic growth and 32 value-creative acquisitions that have strengthened the Company's market positions in attractive niches of the animal health market and changed the composition and profile of the Company.

Vimian's new financial targets

- Adjusted EBITA above EUR 300m by 2030.
- Net debt in relation to pro-forma adjusted LTM EBITDA shall not exceed 3.0x, subject to flexibility to fund acquisitions (unchanged).

Vimian aims to deliver adjusted EBITA above EUR 300m by 2030, and more than half of the adjusted EBITA growth should be organic. The target is not contingent on further capital injections. The new target shall be achieved through:

- Double-digit organic revenue growth,
- Like-for-like adjusted EBITA margin increase,
- Improved cash generation,
- Value-creative acquisitions to complement existing offering, enter new geographies or gain access to new services and technologies.

"The new financial target of adjusted EBITA above EUR 300m by 2030 reflects Vimian's ambition to build shareholder value through strong profit growth with a high level of cash generation. Vimian's strategy remains the same, we will continue to strengthen our global market positions in selected niches of the animal health market with unmet medical needs and sustainable above market growth potential", says Patrik Eriksson, CEO Vimian Group.

Previous financial targets

- Vimian shall achieve a sales CAGR of at least 30 per cent in the medium term of which organic sales growth exceeds 15 per cent annually.
- Vimian shall achieve an adjusted EBITA margin of approximately 35 per cent in the medium term and an annual adjusted EBITA above EUR 200 million in 2025.
- Net debt in relation to pro-forma Adjusted LTM EBITDA shall not exceed 3.0x, subject to flexibility to fund acquisitions.

Telephone conference

An audiocast with CEO Patrik Eriksson and CFO Carl-Johan Zetterberg Boudrie will be organised for investors, analysts and media at 08.30 (CET) today 8 March, 2024.

To attend the teleconference:

Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference/user ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id=5009822>

To attend the webcast:

<https://ir.financialhearings.com/investorcall>

The Board of Directors of Vimian Group AB (publ)

For further information, please contact:

Carl-Johan Zetterberg Boudrie

CFO

carl-johan.zetterberg@vimian.com

+46 703 35 84 49

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 736 26 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 80 markets, has 1,000 employees and annual revenues of approximately EUR 330 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.

This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-08 07:30 CET.

Attachments

[Vimian announces new financial targets](#)
